Is tremelimumab/tremelimumab targeted or immunotherapy?

Tremelimumab/tremelimumab) is an immunotherapy drug that belongs to the anti-CTLA-4 antibody category. It can block the activity of CTLA-4, contribute to T cell activation, initiate T cell immune response to cancer, and promote cancer cell death. Therefore, tremelimumab/tematumumab is an immunotherapy drug.

Tremelimumab has been shown to have some efficacy against certain types of cancer, including hepatocellular carcinoma and non-small cell lung cancer. It can increase patient survival and reduce the risk of tumor progression. However, its specific efficacy and indications depend on the patient's condition and cancer type. Like other immunotherapy drugs, tremelimumab may cause some side effects. Common side effects include fatigue, rash, loss of appetite, diarrhea, etc. More serious side effects may include immune-related inflammatory reactions such as hepatitis, thyroiditis, and enteritis. When receiving tremelimumab treatment, patients need to be closely monitored and communicate with their doctors, as well as undergo regular examinations.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.